Evaluation of Yavaksharadi Churna in adults with Tamaka Shwasa (Bronchial Asthma)

An Exploratory Clinical Study To Evaluate The Efficacy Of Yavaksharadi Churna In The Management of Tamaka Shwasa (Bronchial Asthma) In Adults - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106318

Enrollment

Registered

2026-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J452- Mild intermittent asthma Health Condition 2: J453- Mild persistent asthma Health Condition 3: J454- Moderate persistent asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.The patients between the age group of 20 to 60 years of either sex presenting with clinical features of Tamaka Shwasa (Bronchial asthma) like, breathlessness, wheezing, paroxysm of attack, cough etc. irrespective of Sex and Religion. 2. Newly diagnosed cases of Bronchial Asthma having FEV1 and PEFR greater than 60 percent of predicted value. 3. Mild Intermittent, Mild Persistent and Moderate Persistent Cases of Bronchial Asthma (As per WHO GINA Guideline). 4. Patient willing to sign the consent form. 5. Never smokers.

Exclusion criteria

Exclusion criteria: 1. Age below 20 and above 60 years. 2. Patients having Acute exacerbation of Bronchial Asthma. 3. Patients having FEV1 and PEFR less than 60 percent of predicted value. 4. Diagnosed cases of Tuberculosis, Pneumonia, COPD and other acute and chronic pulmonary disorders. 5.Patients having asthma due to secondary causes such as drug induced like aspirin. 6. Pregnant women and lactating mothers. 7. Patients having concomitant systemic illness like Uncontrolled Hypertension, Poorly controlled Diabetes Mellitus, Renal failure, Malignancy, Acute or Chronic Liver Disease. 8. HIV positive cases.

Design outcomes

Primary

Measure	Time frame
Symptomatic ChangesTimepoint: 30th day and 45th day	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Bhagyashri Andhale

PGIA Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University

bkmudgal9@gmail.com9460318138

Outcome results